CDR2 and ovarian carcinoma: Early work by Furneaux et al. suggested that anti-Yo antibodies labeled cells within ovarian carcinomas from those individuals with anti-Yo antibody-associated paraneoplastic cerebellar degeneration but did not label tumors from control patients with similar malignancies (45).